By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Investigators publish new report on Biotechnology. According to news reporting from Berlin, Germany, by NewsRx journalists, research stated, "The adoptive transfer of lymphocytes genetically engineered to express tumor-specific antigen receptors is a potent strategy to treat cancer patients. T lymphocyte subsets, such as na < ve or central memory T cells, selected in vitro prior to genetic engineering have been extensively investigated in preclinical mouse models, where they demonstrated improved therapeutic efficacy."
The news correspondents obtained a quote from the research from German Rheumatism Research Center, "However, so far, this is challenging to realize in the clinical setting, since good manufacturing practices (GMP) procedures for complex cell sorting and genetic manipulation are limited. To be able to directly compare the immunological attributes and therapeutic efficacy of na < ve (T-N) and central memory (T-CM) CD8(+) T cells, we investigated clinical-scale procedures for their parallel selection and in vitro manipulation. We also evaluated currently available GMP-grade reagents for stimulation of T cell subsets, including a new type of anti-CD3/anti-CD28 nanomatrix. An optimized protocol was established for the isolation of both CD8(+) T-N cells (CD4(-)CD62L(+)CD45RA(+)) and CD8(+) T-CM (CD4(-)CD62L(+)CD45RA(-)) from a single patient. The highly enriched T cell subsets can be efficiently transduced and expanded to large cell numbers, sufficient for clinical applications and equivalent to or better than current cell and gene therapy approaches with unselected lymphocyte populations."
According to the news reporters, the research concluded: "The GMP protocols for selection of T-N and T-CM we reported here will be the basis for clinical trials analyzing safety, in vivo persistence and clinical efficacy in cancer patients and will help to generate a more reliable and efficacious cellular product."
For more information on this research see: Clinical-scale selection and viral transduction of human na < ve and central memory CD8(+) T cells for adoptive cell therapy of cancer patients. Cancer Immunology Immunotherapy, 2013;62(10):1563-1573. Cancer Immunology Immunotherapy can be contacted at: Springer, 233 Spring St, New York, NY 10013, USA (see also technology.html">Biotechnology).
Our news journalists report that additional information may be obtained by contacting A. Casati, Leibniz Assoc, German Rheumatism Res Center DRFZ Berlin, Berlin, Germany. Additional authors for this research include A. Varghaei-Nahvi, S.A. Feldman, M. Assenmacher, S.A. Rosenberg, M.E. Dudley and A. Scheffold.
Keywords for this news article include: Biotechnology, Berlin, Europe, Germany, Genetics, Oncology, Immunology, Blood Cells, CD Antigens, CD4 Antigens, CD8 Antigens, Cell Therapy, HIV Receptors, Bioengineering, Differentiation, Membrane Proteins, Biological Factors, Biological Therapy, Pre-Trial Research, Cancer Gene Therapy, T-Lymphocyte Antigens
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC